(26), the authors found that combining UTMD with intraperitoneal administration of checkpoint inhibition and IFN-β plasmid transfection could significantly reduce tumor volume and enhance T cell infiltration by recruiting effective local and distant tumor site immune cells. The gene discussed is IFNB1; the disease is neoplasm.